Inclusion Criteria:

• Signed informed consent before initiation of any study-related procedure and agreement to comply with all protocol-specific procedures
• Stable angina pectoris (CCS Class 1, 2, 3, 4) or unstable angina (Braundwald class 1-3, B) or documented silent ischemia
• Baseline ECG with stable sinus rhythm and no signs of ischemia and with no Q waves, bundle branch block or IV conduction disturbances.
• Normal left ventricular wall motion on left ventricular angiogram or on echocardiogram with preserved systolic global LV function
• Non-occlusive stenosis, located in the proximal segments of the left anterior descending artery (LAD) (segments 6 and/or 7) and/or circumflex artery (CFX) (segments 11 and/or 12) or right coronary artery (RCA) (segments 1, 2 and/or 3) for which there is clinical indication to percutaneous treatment with coronary stenting
• Successful PCI with stenting on the target vessel
• Older than 18 years and younger than 80 years of age

Exclusion Criteria:

• Active ischemia at the initiation of the study procedure
• Non-ST segment elevation myocardial infarction
• History or ECG evidence of prior MI in the territory supplied by the vessel undergoing PCI, IV conduction defects/baseline ST-segment abnormalities on the surface ECG
• Moderate to severe aortic or mitral valve disease
• Evidence of LV hypertrophy on the echocardiogram IVS > 13 and/or PW > 13mm
• Angiographically visible collateral vessels to the target vessel
• Hypertension not adequately controlled by anti-hypertensive therapy at the time of study entry (> 140/100mmHg)
• Uncompensated congestive heart failure or signs of pulmonary edema
• Significant hemodynamic compromise and/or cardiogenic shock requiring inotropic or pressor support
• Contraindications to standard drugs for coronary intervention and coronary heart disease: aspirin, heparin, low molecular weight heparin, clopidogrel, contrast dye
• Confirmed pregnancy
• Systemic mastocytosis
• Hypoxemia (need for mechanical ventilation
• Known history of COPD with FEV 1s < 1.0 liter
• Renal impairment: creatinine > 1.6 mg/dl
• Participation in another trial with an investigational drug or device including follow-up period, within the last 30 days before enrollment

Additional exclusion criteria at the end of PCI (before randomization)

• Coronary TIMI flow in the treated artery is less than 3
• Serious arrhythmias during/following the PCI was noted
• Coronary spasm following PCI
• Any deterioration in the subject's "risk" status between informed consent and randomization